Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung cancer
Pharma
Biokin, BMS' bispecific ADC hits goal in China lung cancer trial
With the positive readout in EGFR-mutated NSCLC, iza-bren poses another threat to TROP2-targeted ADCs.
Angus Liu
Aug 18, 2026 11:18am
GSK’s first lung cancer approval, a new IPO path and more
Jul 24, 2026 9:42am
Nuvalent deal delivers GSK’s first-ever lung cancer approval
Jul 22, 2026 3:15pm
Roche tops cancer reputation rankings as AstraZeneca climbs back
Jul 2, 2026 6:00am
Zepzelca saga takes another turn with ph. 3 lung cancer flop
Jun 12, 2026 10:48am
Boehringer touts promising launches of Hernexeos, Jascayd
Mar 25, 2026 10:57am
